Home Industry Logistics AD Ports Group to boost Hayat Biotech’s global expansion with new MoU The MoU will also boost Hayat Biotech’s global logistics and distribution activities through AD Ports Group’s logistics network, which includes its cold and ultra-cold pharma hub based in KIZAD by Gulf Business July 13, 2022 AD Ports Group and UAE-based Hayat Biotech have signed a memorandum of understanding (MoU) to enable the latter to set up manufacturing centres around the globe and provide logistics solutions to serve its international markets. The agreement covers the shipping of strategic construction supplies, including containers, machinery, raw materials and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities. The facilities – once complete – will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced Covid-19 vaccine in the UAE and Arab world. Read: UAE approves new Sinopharm vaccine to be used as booster jabs As part of the collaboration, the distribution will be handled by the HOPE Consortium, which is said to operate one of the largest and most complete end-to-end pharma supply chains today. Alongside the Department of Health – Abu Dhabi, Etihad Cargo, Maqta Gateway, Rafed, and SkyCell, AD Ports Group is one of the founding members of the HOPE Consortium, which is helping lead the distribution of Covid-19 vaccines to all parts of the globe. The partnership has handled over 250 million vaccine doses across 60 countries. Read: Abu Dhabi’s Hope Consortium to facilitate worldwide distribution of Covid-19 vaccine Captain Mohamed Juma Al Shamisi, MD and group CEO of AD Ports Group, and chairman of the HOPE Consortium’s Executive Committee, said: “As a nation, the UAE continues to take significant steps towards enabling global access to pharmaceutical products and supplies. Thanks to our partnership with Hayat Biotech, we are cementing the pivotal role that AD Ports Group and the HOPE Consortium are playing in supporting our healthcare industry’s efforts to serve communities and markets all around the world.” .@ADPortsGroup and Hayat Biotech are partnering to advance the UAE-based pharma company’s distribution of vital pharmaceutical products around the world, including the Arab World’s first indigenously produced Covid-19 vaccine, Hayat-Vax, through #AbuDhabi’s HOPE Consortium. pic.twitter.com/mhgnFRv20C — مكتب أبوظبي الإعلامي (@admediaoffice) July 13, 2022 Robert Sutton, CEO of Logistics Cluster, AD Ports Group, said: “We are pleased to leverage our complete end-to-end logistics solutions, which cover everything from transportation and storage, to monitoring and delivery of pharma supplies, anywhere around the world. Capitalising on Abu Dhabi’s strategic position as a global gateway, we are working together to help position the emirate as a leading global logistics hub for the life sciences sector.” Naser Al Yammahi, deputy CEO, Hayat Biotech, said: “The world is facing fundamental challenges that are affecting our wellbeing, health, and quality of life; therefore, we made it our responsibility to deliver innovative biotechnological capabilities around the globe. Thanks to the partnership with AD Ports Group, we are looking to further expand our distribution network to deliver necessary biopharmaceutical products to improve the health of our nation and across the globe.” In recent news, AD Ports Group and Uzbekistan’s oil and gas company Sanoat Energetika Guruhi (SEG) signed an agreement to establish a joint venture for developing logistics infrastructure and services in Uzbekistan. Read: Abu Dhabi’s AD Ports Group, SEG to create logistics cluster in Uzbekistan Tags AD Ports Group Hayat Biotech Logistics Pharma supply chain 0 Comments You might also like AD Ports Group awards construction contract for new terminal in Egypt DP World begins dredging work at Sengal’s Port of Ndayane Abu Dhabi Crown Prince inaugurates CMA Terminals Khalifa Port Informa’s Adam Andersen on how CPHI ME is building bridges in the pharma sector